Cantor Fitzgerald Predicts LLY FY2025 Earnings

Eli Lilly and Company (NYSE:LLY) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Eli Lilly and Company in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings of $22.29 per share for the year. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $12.98 per share.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year.

Several other equities research analysts also recently weighed in on the stock. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 1st. Citigroup lifted their target price on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Barclays lowered their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective on the stock. Finally, Truist Financial boosted their target price on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.22.

Eli Lilly and Company Trading Up 2.2 %

Eli Lilly and Company stock opened at $741.98 on Wednesday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $704.38 billion, a price-to-earnings ratio of 80.21, a price-to-earnings-growth ratio of 1.52 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $614.82 and a 12 month high of $972.53. The business’s fifty day simple moving average is $779.00 and its two-hundred day simple moving average is $852.83.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.81%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company declared that its board has authorized a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of LLY. Drive Wealth Management LLC grew its position in shares of Eli Lilly and Company by 8.0% during the fourth quarter. Drive Wealth Management LLC now owns 2,495 shares of the company’s stock worth $1,926,000 after purchasing an additional 185 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $105,000. Tennessee Valley Asset Management Partners grew its holdings in Eli Lilly and Company by 60.0% during the 4th quarter. Tennessee Valley Asset Management Partners now owns 480 shares of the company’s stock valued at $371,000 after buying an additional 180 shares in the last quarter. Narwhal Capital Management raised its position in shares of Eli Lilly and Company by 4.9% during the fourth quarter. Narwhal Capital Management now owns 22,456 shares of the company’s stock valued at $17,336,000 after buying an additional 1,053 shares during the last quarter. Finally, Peak Financial Management Inc. lifted its holdings in shares of Eli Lilly and Company by 59.4% in the fourth quarter. Peak Financial Management Inc. now owns 365 shares of the company’s stock worth $282,000 after buying an additional 136 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.